Baricitinib

Drug Profile

Baricitinib

Alternative Names: INCB-028050; INCB-28050; LY-3009104; Olumiant

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Eli Lilly; Incyte Corporation
  • Class Acetonitriles; Antipsoriatics; Antirheumatics; Azetidines; Pyrazoles; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Rheumatoid arthritis
  • Phase II Atopic dermatitis; Systemic lupus erythematosus
  • Phase Unknown Giant cell arteritis; Psoriatic arthritis
  • Discontinued Diabetic nephropathies; Psoriasis

Most Recent Events

  • 01 Mar 2017 Eli Lilly completes a phase II trial in Atopic dermatitis in USA and Japan (PO) (NCT02576938)
  • 15 Feb 2017 Updated efficacy and adverse events data from the phase III RA-BEAM trial released by Eli Lilly and Incyte Corporation
  • 13 Feb 2017 Registered for Rheumatoid arthritis (Treatment-naive, Treatment-experienced) in European Union, Norway, Iceland and Liechtenstein (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top